Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

The Food and Drug Administration (FDA) has expanded the approval of Jascayd ® (nerandomilast), an oral phosphodiesterase 4 inhibitor, to include treatment of progressive pulmonary fibrosis (PPF) in ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...

Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD (nerandomilast) ...

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...

The FDA approved nerandomilast tablets for adults with progressive pulmonary fibrosis, according to an industry press release ...

Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This groundbreaking medication goes beyond merely alleviating ...